Novo Nordisk and Viatris have agreed to resolve a patent dispute over Novo's blockbuster weight-loss drugs Ozempic and Wegovy ...

Novo Nordisk (NVO) and Viatris (VTRS) have reportedly reached an agreement in their dispute over U.S. patents protecting Novo ...

Novo Nordisk ($NVO) and Viatris ($VTRS) have agreed to settle a dispute over patents for Novo’s weight-loss drugs, Ozempic ...

With a new patent settlement, generic partners Mylan and Natco have cleared one hurdle to a potential U.S. launch of their ...

Novo Nordisk and Mylan Pharmaceuticals, now part of Viatris, have settled their patent dispute over Novo’s blockbuster ...

Qure.ai — which is headquartered in India — closed a $65 million Series D financing round. When asked whether the startup is ...

The program is examining the effectiveness of a protocol meant to ensure safety for pilots and air traffic controllers on ...

DelveInsight's Hormone Replacement Therapy Market Insights report provides the current and forecast market analysis, ...

Pharmaceutical giant Pfizer is set to reduce its workforce in Ireland as it faces ongoing challenges in the wake of the COVID ...

The hormone replacement therapy market is witnessing substantial growth due to the rising occurrence of hormonal and targeted conditions such as menopause and osteoporosis, coupled with the ...

The current biggest selling competition in this market is Viatris' EpiPen ... same class of drug as Eli Lilly and Company (LLY) and Novo Nordisk A/S's (NVO) "miracle" weight loss drugs Zepbound ...

Despite continuous advances in pharmacotherapy, atherosclerotic cardiovascular disease remains the world's leading killer. Atherosclerosis relates not only to an increased level of cholesterol, but ...